Results 41 to 50 of about 28,123 (301)

Label‐Free FET Based Biosensor for Detection of Engineered CAR T‐Cells at Single Cell Resolution

Advanced Sensor Research, EarlyView.
A silicon nanowire field‐effect transistor (SiNW FET) biosensor that allows for label‐free, real‐time detection and quantification of engineered Chimeric Antigen Receptor (CAR) T‐cells at single‐cell resolution is presented. By mimicking the CAR‐specific antigen interface, the platform provides highly selective analysis of individual cell surface ...
Trang Anh Nguyen‐Le, Isli Cela, Anja Feldmann, Chang‐Ki Baek, Michael Bachmann, Larysa Baraban   +5 more
wiley   +1 more source

Genetic Engineering Methods in Primary T Cells

Advanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

Nature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku, Xuping Xie, Jianqing Lin, Peng Gao, Bin Wu, Abbas El Sahili, Hang Su, Yang Liu, Xiaohua Ye, Eddie Yongjun Tan, Xin Li, Xuejun Fan, Boon Chong Goh, Wei Xiong, Hannah Boyd, Antonio E. Muruato, Hui Deng, Hongjie Xia, Jing Zou, Birte K. Kalveram, Vineet D. Menachery, Ningyan Zhang, Julien Lescar, Pei-Yong Shi, Zhiqiang An   +24 more
doaj   +1 more source

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Journal for ImmunoTherapy of Cancer, 2021
Background T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity in hematologic ...
Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers   +13 more
doaj   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
doaj   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects

Advanced Science, EarlyView.
Y332D, a bispecific antibody that simultaneously blockades VEGF and TGF‐β, counteracted negative RT effects that are attributed to the upregulation of TGF‐β and VEGF, as well as further enhanced the immunostimulatory effects of RT, thereby reprograming the TME from immune “cold” to inflamed state and forming an effective in‐situ vaccine that eradicate ...
Lijuan Lyu, Ming Yi, Ji Chen, Jing Zhang, Xiaobin Ma, Xiaojun Zhang, Liang Zeng, Yan Xue, Haimei Wen, Yujiao Deng, Pengfei Zhou, Kongming Wu, Huafeng Kang, Zhijun Dai   +13 more
wiley   +1 more source